Thalidomide, a Rational Agent for Treatment of Multicentric Reticulohistiocytosis

Dermatology Case Reports
doi 10.35248/2684-124x.19.4.152
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Longdom Group

Related search

Targetable Driver Mutations in Multicentric Reticulohistiocytosis

Haematologica
Hematology
2019English

Multicentric Reticulohistiocytosis in the Course of Undifferentiated Connective Tissue Disease

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2019English

Single-Agent Thalidomide for Treatment of First Relapse Following High-Dose Chemotherapy in Patients With Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

Reticulohistiocytosis

Acta Radiologica
1957English

Multicentric Reticulohistiocytosis (MRH): First Case Report With Tenosynovial Fluid Analysis and Tenosynovial Histology Demonstrating the Classic Histologic Findings

Open Journal of Rheumatology and Autoimmune Diseases
2016English

Immunological Consequences of Thalidomide Treatment in Sjogren's Syndrome

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2006English

Rational Use of Moxifloxacin for Tuberculosis Treatment

The Lancet Infectious Diseases
Infectious Diseases
2011English

Rational Design of Nanomaterials for Water Treatment

Nanoscale
Materials ScienceNanotechnologyNanoscience
2015English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology
MedicineHematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy